➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Merck
McKesson
Baxter
Colorcon

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,925,209

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,925,209
Title:Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
Abstract: Compositions containing conjugates of heparosan polymer with at least one drug are disclosed, along with methods of production and use thereof.
Inventor(s): DeAngelis; Paul L. (Edmond, OK)
Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (Norman, OK)
Application Number:14/536,003
Patent Claims:1. A pharmaceutical composition comprising: at least one heparosan polymer-drug conjugate, comprising: at least one heparosan polymer; and at least one therapeutic drug covalently conjugated to the at least one heparosan polymer, wherein the at least one therapeutic drug comprises at least one polypeptide, and wherein the at least one therapeutic drug remains therapeutically active after conjugation and is not an adjuvant; and wherein the pharmaceutical composition is a sterile pharmaceutical formulation in a unit dosage format.

2. The pharmaceutical composition of claim 1, wherein the at least one therapeutic drug is selected from the group consisting of Granulocyte Colony Stimulating Factor (G-CSF), Interferon, Insulin, Growth Hormone (hGH), Glucagon-like peptide-1 (GLP-1), Phenylalanine Ammonia-Lyase (PAL), L-Asparaginase (Asp), Anti-TNF alpha Fab', and combinations thereof.

3. The pharmaceutical composition of claim 1, wherein the at least one heparosan polymer has a mass in a range of from about 600 Da to about 4.5 MDa.

4. The pharmaceutical composition of claim 1, wherein the at least one heparosan polymer comprises an activated group with which a group on the at least one therapeutic drug has reacted to effect the covalent conjugation.

5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a plurality of drug-heparosan polymer conjugates, and wherein the plurality of heparosan polymers present in the drug-heparosan polymer conjugates is polydisperse in size.

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a plurality of drug-heparosan polymer conjugates, and wherein the plurality of heparosan polymers present in the drug-heparosan polymer conjugates is substantially monodisperse in size.

7. The pharmaceutical composition of claim 1, wherein the at least one heparosan polymer is a linear chain.

8. The pharmaceutical composition of claim 1, wherein the at least one heparosan polymer has a branched geometry.

9. The pharmaceutical composition of claim 1, wherein at least one of: (a) the drug-heparosan conjugate exhibits increased retention in blood and/or lymphatic circulation of a mammalian patient when compared to drug alone; and (b) the drug-heparosan conjugate exhibits reduced occurrence of accumulation in organs and/or tissues of a mammalian patient when compared to drug alone.

10. A method for preparing a pharmaceutically active heparosan polymer-drug conjugate, wherein the drug comprises at least one polypeptide, the method comprising the step of: reacting at least one therapeutic drug with at least one heparosan polymer under conditions sufficient to effect covalent conjugation of the at least one therapeutic drug and the at least one heparosan polymer to form a reaction mixture containing one or more drug-heparosan polymer conjugates, wherein the at least one therapeutic drug comprises at least one polypeptide, and wherein the at least one therapeutic drug remains therapeutically active after conjugation and is not an adjuvant; and forming a sterile pharmaceutical formulation comprising the drug-heparosan polymer conjugates in a unit dosage format for administration to a mammalian patient.

11. The method of claim 10, wherein the at least one heparosan polymer has a mass in a range of from about 600 Da to about 4.5 MDa.

12. The method of claim 10, further comprising the step of modifying the heparosan polymer prior to reacting with the at least one therapeutic drug to provide at least one reactive group on the at least one heparosan polymer with which a group on the at least one therapeutic drug reacts to effect the covalent conjugation of the at least one therapeutic drug to the at least one heparosan polymer.

13. The method of claim 10, wherein the reaction mixture comprises a plurality of drug-heparosan polymer conjugates, and wherein the plurality of heparosan polymers present in the drug-heparosan polymer conjugates is polydisperse in size.

14. The method of claim 10, wherein the reaction mixture comprises a plurality of drug-heparosan polymer conjugates, and wherein the plurality of heparosan polymers present in the drug-heparosan polymer conjugates is substantially monodisperse in size.

15. The method of claim 10, wherein the at least one heparosan polymer is a linear chain.

16. The method of claim 10, wherein the at least one heparosan polymer has a branched geometry.

17. The method of claim 10, wherein at least one of: (a) the drug-heparosan conjugate exhibits increased retention in blood and/or lymphatic circulation of a mammalian patient when compared to drug alone; and (b) the drug-heparosan conjugate exhibits reduced occurrence of accumulation in organs and/or tissues of a mammalian patient when compared to drug alone.

18. The method of claim 10, wherein the at least one therapeutic drug is selected from the group consisting of a cytokine, a hormone, an enzyme, an antibody, an antibody fragment, an aptamer, and combinations thereof.

19. The method of claim 10, wherein the at least one therapeutic drug is selected from the group consisting of Granulocyte Colony Stimulating Factor (G-CSF), Interferon, Insulin, Growth Hormone (hGH), Glucagon-like peptide-1 (GLP-1), Phenylalanine Ammonia-Lyase (PAL), L-Asparaginase (Asp), Anti-TNF alpha Fab', and combinations thereof.

20. The pharmaceutical composition of claim 1, wherein the at least one heparosan polymer is characterized as being substantially non-antigenic, substantially non-immunogenic, and substantially biologically inert within extracellular compartments of a mammalian patient, being stable in the mammalian bloodstream, and being degraded intracellularly in the mammalian patient.

21. The pharmaceutical composition of claim 1, wherein the sterile pharmaceutical formulation in a unit dosage format is for injection into the patient.

22. The method of claim 10, wherein the at least one heparosan polymer is characterized as being substantially non-antigenic, substantially non-immunogenic, and substantially biologically inert within extracellular compartments of a mammalian patient, being stable in the mammalian bloodstream, and being degraded intracellularly in the mammalian patient.

23. The method of claim 10, wherein the sterile pharmaceutical formulation in a unit dosage format is for injection into the patient.

24. The pharmaceutical composition of claim 1, wherein the at least one therapeutic drug is selected from the group consisting of a cytokine, a hormone, an enzyme, an aptamer, and combinations thereof.

25. The pharmaceutical composition of claim 1, wherein the at least one therapeutic drug comprises a plurality of therapeutic drugs conjugated to the at least one heparosan polymer.

26. The pharmaceutical composition of claim 1, wherein the at least one therapeutic drug comprises an antibody or an antibody fragment.

27. The method of claim 10, wherein the at least one heparosan polymer is reacted with a plurality of therapeutic drugs under conditions sufficient to effect covalent conjugation of the plurality of therapeutic drugs to the at least one heparosan polymer.

Details for Patent 9,925,209

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (Norman, OK) 2028-03-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Merck
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.